About 9 results found for searched term "IRAK4-IN-7" (0.135 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M6258 | IRAK4-IN-7 | IRAK |
| CA-4948; CA4948; Emavusertib | ||
| IRAK4-IN-7 is a selective, potent and orally active inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4) that regulates IRAK4 function in the TLR and IL-1R signaling cascades. It has good pharmacokinetic characteristics and antitumor activity in vitro and in vivo. | ||
| M42000 | IRAK4-IN-27 | IRAK |
| IRAK4-IN-27 is a potent, selective inhibitor of IRAK4, with IC50 of 8.7 nM. | ||
| M10832 | HPK1-IN-7 | MAPKAPK2/MAP3K/MAP4K |
| HPK1-IN-7 is a potent inhibitor of the orally active HPK1 (hematopoietic progenitor kinase 1, MAP4K1) (IC50=2.6 nM), with excellent family and kinase group selectivity. The HPK1-IN-7 is selective for IRAK4 (59 nM) and GLK (140 nM). HPK1-IN-7 combined with anti-PD1 has shown powerful efficacy in MC38 cogenic tumor models. | ||
| M20807 | IRAK4-IN-1 | IRAK |
| Compound 23 | ||
| IRAK4-IN-1 is an interleukin-1 receptor associated kinase 4 (IRAK4) inhibitor with IC50 of 7 nM. | ||
| M21784 | AZ1495 | IRAK |
| AZ1495 is a weak base and orally active, potent interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor with a Kd value of 0.0007 μM.AZ1495 has good physicochemical and kinase selectivity for IRAK4 and IRAK1, with IC50 values of 0.005 μM and 0.023 μM, respectively.AZ1495 is used in studies of diffuse large B-cell lymphoma (DLBCL). | ||
| M41998 | IRAK4-IN-25 | IRAK |
| IRAK4-IN-25 is an orally acitve and potent IRAK4 inhibitor (IC50=7.3 nM), with low clearance (Cl=12 mL/min/kg). | ||
| M54681 | IRAK4-IN-21 | IRAK |
| IRAK4-IN-21 is an orally potent, selective, and potent IRAK4 inhibitor with IC50 values of 5 and 56 nM for IRAK4 and TAK1, respectively.IRAK4-IN-21 potently inhibits the production of IL-23 (IC50=0.17 µM) and may be useful in studies related to autoimmune diseases such as plaque psoriasis and psoriasis vulgaris. arthritis). | ||
| M54685 | IRAK4-IN-22 | IRAK |
| IRAK4-IN-22 is an orally potent and selective potent IRAK4 inhibitor with IC50 values of 3 and 17 nM for IRAK4 and TAK1, respectively.In addition, IRAK4-IN-21 potently inhibits the production of IL-23 (IC50=0.10 µM), which may be useful in studies related to autoimmune diseases such as plaque psoriasis and psoriasis vulgaris. arthritis). | ||
| M54684 | HS271 | IRAK |
| HS271 is an orally potent and selective IRAK4 inhibitor with an IC50 value of 7.2 μM. In addition, HS271 has superior in vitro enzymatic and cellular activities. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.
